UK Markets close in 4 hrs 27 mins

Fc Fusion Therapeutics Market, 2030 by Target Indications, Type of Fusion Molecule, Route of Administration and Key Geographical Regions - ResearchAndMarkets.com

·6-min read

DUBLIN, December 01, 2021--(BUSINESS WIRE)--The "Fc Fusion Therapeutics Market - Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

The "Fc Fusion Therapeutics Market Report" report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies till 2030. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and the future growth opportunities for Fc fusion therapeutics, over the next few years. Based on multiple parameters, such as target patient population, likely adoption rate and the annual treatment cost, we have provided informed estimates on the evolution of the market for the period 2021-2030.

Since the approval of Enbrel, a recombinant human tumor necrosis factor (TNF) receptor-Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion therapies have evolved into a prominent class of therapeutics. Currently, 13 Fc fusion drugs are commercially available, while around 50 molecules are under development for various disease indications.

Some of the Fc fusion therapeutics including Arcalyst (recurrent pericarditis, March 2021), Reblozyl (beta-thalassemia, September 2020) and Eylea (diabetic retinopathy, May 2019) were approved recently. These molecules combine the beneficial pharmacological properties of biologically active ligands with the properties of the crystallizable fragment (Fc) domain of an immunoglobulin G (IgG).

It is worth highlighting that these advanced variants of immunoglobulin derived therapeutic candidates are protected from lysosomal degradation once they are taken up by endothelial cells and later released back into the bloodstream by binding of the Fc-fragment to FcRn receptors present in endosomes. This prolongs the exposure of the pharmacologically active moieties to the target tissue thereby, increasing their therapeutic efficacy.

Given their ability to extend the serum half-life of biologically active proteins, these disease-modifying interventions find applications across different therapeutic areas (including but not limited to oncological disorders, neurological disorders, respiratory disorders, rare genetic disorders).

Presently, several drug developers are actively engaged in the development of novel Fc fusion therapies with enhanced efficacy. The research in this field is focused on improving the stability and solubility of pharmacologically active moiety, thereby, improving its therapeutic potential.

Further, several big pharma players have demonstrated interest in Fc fusion therapeutics and are investing both time and capital in this domain. The activity in this segment of the industry has also attracted the attention of both private and public sector investors/investment funds, which have extended financial support to the initiatives of capable developer companies.

Moreover, the market has witnessed substantial partnership activity over the last few years. Given the ongoing efforts and the encouraging clinical trial results, the Fc fusion therapies market is poised to witness healthy growth as more drug candidates get approved and marketed over the coming decade.

Key Questions Answered

  • Who are the leading industry players involved in the development of Fc fusion therapeutics?

  • Which geographies are the most active in conducting clinical trials on Fc fusion therapeutics?

  • Which are the leading funding organizations providing grants for Fc fusion therapeutics?

  • Which partnership models are commonly adopted by industry stakeholders in the development of Fc fusion therapeutics?

  • How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Key Questions Answered

1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Overview of Fc Fusion Therapeutics

3.2. Components of Fc Fusion Therapeutics

3.3. Mechanism of Action

3.4. Types of Fc Fusion Therapeutics

3.5. Applications of Fc Fusion Therapeutics

3.6. Advantages of Fc Fusion Therapeutics over Other Biological Moieties

3.7. Future Perspectives

4. PIPELINE REVIEW: MARKETED AND CLINICAL DRUGS

4.1. Analysis Methodology and Key Parameters

4.2. Fc Fusion Therapeutics: Drug Pipeline

4.3. Fc Fusion Therapeutics: Pipeline Analysis

4.4. Fc Fusion Therapeutics: List of Drug Developers

5. COMPANY PROFILES

5.1. Chapter Overview

5.2. Alphamab Oncology

5.2.1. Company Overview

5.2.2. Financial Information

5.2.3. Product Portfolio

5.2.4. Recent Developments and Future Outlook

5.3. Amgen

5.4. Acceleron Pharmaceuticals

5.5. Bristol Myers Squibb

5.6. Sanofi

6. CLINICAL TRIAL ANALYSIS

6.1. Analysis Methodology and Key Parameters

6.2. Fc Fusion Therapeutics: List of Clinical Trials

7. ACADEMIC GRANT ANALYSIS

7.1. Analysis Methodology and Key Parameters

7.2. Fc Fusion Therapeutics: Analysis of Academic Grants

8. PUBLICATION ANALYSIS

8.1. Analysis Methodology and Key Parameters

8.2. Fc Fusion Therapeutics: Recent Publications

8.3. Analysis by Year of Publication

8.4. Word Cloud Analysis: Emerging Focus Areas

8.5. Analysis by Target Therapeutic Area

8.6. Leading Authors: Analysis by Number of Publications

8.7. Key Journals: Analysis by Number of Publications

9. PATENT ANALYSIS

9.1. Analysis Methodology and Key Parameters

9.2. Fc Fusion Therapeutics: Patent Analysis

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Analysis Methodology and Key Parameters

10.2. Partnership Models

10.3. Fc Fusion Therapeutics: List of Partnerships and Collaborations

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

11.1. Forecast Methodology and Key Assumptions

11.2. Global Fc Fusion Therapeutics Market, 2021-2031

11.3. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Target Indication

11.4. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Type of Fusion Molecule

11.5. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Type of Therapy

11.6. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Route of Administration

11.7. Global Fc Fusion Therapeutics Market, 2021-2031: Distribution by Geography

11.8. Fc Fusion Therapeutics: Individual Product Sales Forecasts

11.8.1. ABP 938 (Amgen)

11.8.2. Alprolix (Sanofi)

11.8.3. AnBaiNuo (Hisun Pharmaceuticals)

11.8.4. Arcalyst (Kiniska Pharmaceuticals)

11.8.5. BIVV001 (Sanofi)

11.8.6. CD24Fc (Merck)

11.8.7. Eloctate (Biogen)

11.8.8. EyleaT (Regeneron Pharmaceuticals)

11.8.9. FRSW107 (Zhengzhou Gensciences)

11.8.10. KN035 (Alphamab Oncology)

11.8.11. KN046 (Alphamab Oncology)

11.8.12. Lumitin (Chengdu Kanghong Biotech)

11.8.13. Reblozyl (Bristol-Myers Squibb)

11.8.14. RyzneutaTM (Evive Biotech)

11.8.15. Strensiq (AstraZeneca)

11.8.16. Telitacicept (RemeGen)

12. CASE STUDY: FC PROTEIN ENGINEERED AND GLYCOENGINEERED ANTIBODIES

12.1. Fc Protein Engineered and Glycoengineered Antibodies: Drug Pipeline

12.2. Fc Protein Engineered and Glycoengineered Antibodies: List of Developers

13. CONCLUSION

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/douwvu

View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005645/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting